{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.8","upperLimit":"43.1","value":"35.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"}],"units":"Participants"}],"description":"CyR is based on the prevalence of Ph+ cells. Major cytogenetic response was categorized as either CCyR or partial CyR (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or less than (\\<) 1% positive cells from at least 200 cells analyzed from fluorescent in situ hybridization (FISH). PCyR was achieved when 1 to 35% Ph+ cells were present.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"}],"paramType":"NUMBER","populationDescription":"Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Participants With MCyR at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2","type":"PRIMARY","unitOfMeasure":"percentage of participants"}